case_images: PMC8082310_01
case_images: (A) Octreoscan imaging in December 2015, before de first treatment with 177Lu-DOTATATE. (B) SPECT-CT studies after first and fourth 177Lu-DOTATATE doses. (C) Octreoscan imaging in November 2016, after finishing first treatment with 177Lu-DOTATATE. (D) SPECT-CT studies in December 2015 and November 2016.
case_images: fendo-12-676973-g001.jpg
case_images: PMC8082310_01_fendo-12-676973-g001.jpg
case_images: f1
case_images: The treatment was completed in September 2016 with an important clinical and radiological benefit observed in the SRS ( Figure 1 ) and in the CT scan by RECIST 1.1.
case_images: (A) Octreoscan imaging at tumor recurrence in June 2019. (B) SPECT-CT studies after fifth and sixth 177Lu-DOTATATE doses. (C) Octreoscan imaging after complete 177Lu-DOTATATE re-treatment.
case_images: fendo-12-676973-g002.jpg
case_images: PMC8082310_01_fendo-12-676973-g002.jpg
case_images: f2
case_images: The patient started follow-up with physical examination, laboratory tests, CT scan and SRS every three months, and the disease was controlled until June 2019, when a CT scan showed liver, bone and nodal progression ( Figure 2 ).
case_images: Historic evolution of the patient.
case_images: fendo-12-676973-g003.jpg
case_images: PMC8082310_01_fendo-12-676973-g003.jpg
case_images: f3
case_images: In the current moment, the patient maintains partial response achieved with 177Lu-DOTATATE ( Figure 3 ).